ARS Investment Partners LLC Increases Position in Biohaven Ltd. $BHVN

ARS Investment Partners LLC grew its position in shares of Biohaven Ltd. (NYSE:BHVN) by 12.4% during the fourth quarter, Holdings Channel reports. The firm owned 1,239,600 shares of the company’s stock after acquiring an additional 137,051 shares during the quarter. ARS Investment Partners LLC’s holdings in Biohaven were worth $13,995,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of BHVN. AQR Capital Management LLC raised its holdings in shares of Biohaven by 49.4% in the 1st quarter. AQR Capital Management LLC now owns 114,849 shares of the company’s stock valued at $2,761,000 after buying an additional 37,981 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Biohaven by 32.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company’s stock valued at $1,747,000 after acquiring an additional 17,562 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Biohaven by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company’s stock valued at $14,174,000 after acquiring an additional 41,040 shares in the last quarter. Intech Investment Management LLC increased its stake in Biohaven by 80.3% during the first quarter. Intech Investment Management LLC now owns 61,598 shares of the company’s stock worth $1,481,000 after purchasing an additional 27,433 shares during the period. Finally, Quantbot Technologies LP increased its stake in Biohaven by 1,097.8% during the second quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock worth $125,000 after purchasing an additional 8,102 shares during the period. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Biohaven Price Performance

Shares of NYSE BHVN opened at $8.74 on Friday. The stock’s 50-day simple moving average is $9.57 and its 200-day simple moving average is $10.65. The firm has a market capitalization of $1.32 billion, a PE ratio of -1.54 and a beta of 1.32. Biohaven Ltd. has a fifty-two week low of $7.48 and a fifty-two week high of $18.57. The company has a debt-to-equity ratio of 1.87, a quick ratio of 7.41 and a current ratio of 7.41.

Biohaven (NYSE:BHVN) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). As a group, equities research analysts forecast that Biohaven Ltd. will post -2.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BHVN has been the subject of several recent research reports. TD Cowen raised their price objective on shares of Biohaven from $15.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Royal Bank Of Canada cut their target price on shares of Biohaven from $23.00 to $22.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 5th. Wall Street Zen lowered shares of Biohaven from a “sell” rating to a “strong sell” rating in a report on Sunday, April 26th. Citigroup boosted their price target on shares of Biohaven from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. Finally, Raymond James Financial reaffirmed a “strong-buy” rating on shares of Biohaven in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.27.

Biohaven Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.